FNY Partners Fund LP bought a new position in ResMed Inc. (NYSE:RMD) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 102,553 shares of the medical equipment provider’s stock, valued at approximately $7,892,000. ResMed makes up about 1.3% of FNY Partners Fund LP’s portfolio, making the stock its 15th largest holding. FNY Partners Fund LP owned 0.07% of ResMed as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of the business. YorkBridge Wealth Partners LLC lifted its stake in shares of ResMed by 4.9% in the second quarter. YorkBridge Wealth Partners LLC now owns 1,476 shares of the medical equipment provider’s stock worth $115,000 after buying an additional 69 shares during the last quarter. Creative Planning lifted its stake in shares of ResMed by 97.1% in the second quarter. Creative Planning now owns 1,671 shares of the medical equipment provider’s stock worth $130,000 after buying an additional 823 shares during the last quarter. Toronto Dominion Bank lifted its stake in shares of ResMed by 12.8% in the second quarter. Toronto Dominion Bank now owns 1,740 shares of the medical equipment provider’s stock worth $135,000 after buying an additional 197 shares during the last quarter. Huntington National Bank acquired a new stake in shares of ResMed in the second quarter worth $156,000. Finally, BB&T Investment Services Inc. acquired a new stake in shares of ResMed in the second quarter worth $214,000. 60.38% of the stock is owned by institutional investors.
Shares of ResMed Inc. (NYSE RMD) traded down $0.16 during mid-day trading on Monday, hitting $85.11. 153,500 shares of the stock were exchanged, compared to its average volume of 860,385. ResMed Inc. has a 52 week low of $58.53 and a 52 week high of $87.81. The firm has a market cap of $12,077.45, a PE ratio of 29.66, a price-to-earnings-growth ratio of 1.89 and a beta of 0.79. The company has a current ratio of 4.72, a quick ratio of 3.86 and a debt-to-equity ratio of 0.50.
ResMed (NYSE:RMD) last announced its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.66 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.66. ResMed had a net margin of 16.58% and a return on equity of 21.53%. The company had revenue of $523.66 million during the quarter, compared to analysts’ expectations of $506.08 million. During the same quarter in the prior year, the company posted $0.62 EPS. The business’s revenue was up 12.5% on a year-over-year basis. research analysts forecast that ResMed Inc. will post 3 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 14th. Stockholders of record on Thursday, November 9th will be paid a $0.35 dividend. This represents a $1.40 dividend on an annualized basis and a dividend yield of 1.64%. The ex-dividend date of this dividend is Wednesday, November 8th. ResMed’s dividend payout ratio is 56.68%.
In other news, CFO Brett Sandercock sold 1,250 shares of the company’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $77.56, for a total value of $96,950.00. Following the sale, the chief financial officer now owns 65,941 shares of the company’s stock, valued at approximately $5,114,383.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Peter C. Farrell sold 20,000 shares of the company’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $76.74, for a total transaction of $1,534,800.00. Following the completion of the sale, the director now directly owns 314,800 shares in the company, valued at approximately $24,157,752. The disclosure for this sale can be found here. In the last 90 days, insiders sold 208,253 shares of company stock valued at $16,930,356. Corporate insiders own 1.77% of the company’s stock.
RMD has been the subject of a number of analyst reports. Zacks Investment Research cut shares of ResMed from a “buy” rating to a “sell” rating in a research note on Tuesday, October 24th. Needham & Company LLC restated a “sell” rating on shares of ResMed in a research note on Friday, October 27th. BMO Capital Markets boosted their price objective on shares of ResMed from $70.00 to $74.00 and gave the stock a “market perform” rating in a research note on Friday, October 27th. J P Morgan Chase & Co boosted their price objective on shares of ResMed from $72.00 to $73.00 and gave the stock an “overweight” rating in a research note on Monday, October 30th. Finally, Barclays PLC boosted their price objective on shares of ResMed from $68.00 to $70.00 and gave the stock an “underweight” rating in a research note on Friday, October 27th. Four research analysts have rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company’s stock. ResMed currently has a consensus rating of “Hold” and an average target price of $67.57.
TRADEMARK VIOLATION WARNING: “FNY Partners Fund LP Buys Shares of 102,553 ResMed Inc. (RMD)” was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://transcriptdaily.com/2017/11/27/fny-partners-fund-lp-buys-shares-of-102553-resmed-inc-rmd.html.
ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.
Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.